FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250069596> ?p ?o ?g. }

• W4250069596 endingPage "3783" @default.
• W4250069596 startingPage "3783" @default.
• W4250069596 abstract "Abstract Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for the treatment of EGFR-mutant non-small lung cancer (NSCLC). In almost all cases, however, the response duration is limited and resistance ultimately emerges. Transformation of NSCLC to small cell lung cancer (SCLC) occurs as one of the resistance mechanisms to EGFR-TKIs. To date, the mechanism associated with this transformation is largely unknown, necessitating the need to establish an effective treatment strategy for patients with transformed SCLC (tSCLC). Methods: We isolated cancer cells that grow as floating aggregates (F) and adherent monolayers (Ad) from the pleural effusion of three patients with tSCLC to establish patient derived cell lines (DFCI112F, DFI112ad, DFCI190F, DFCI190ad, DFCI283F, DFCI283ad). In parallel, patient derived xenograft (PDX) models from these patients were successfully established by subcutaneous implantation of pleural effusions in NSG mice. Transcriptomic and genomic characterization of the cell lines were performed using whole-exome sequencing (WES) and RNA sequencing. These cell lines were further treated with a panel of agents, to screen for effective combination therapies. Results: Biological characterization of the created cell lines revealed that the floating aggregates have neuroendocrine (NE) features, while the adherent cell population presents non-NE/mesenchymal characteristics. The histology of the PDX tumors was confirmed as SCLC. According to WES, all tSCLC cell lines retained the original activating EGFR mutations. RB1 and TP53 were universally inactivated. Co-culturing the floating-NE cells with the adherent non-NE cells promoted the proliferation of the floating-NE cells in vitro. NE cells (DFCI112F) and non-NE cells (DFCI112ad) were injected into nude mice either as single or admixed populations. Tumor growth was observed only in admixed cell populations. In an effort to target both NE and non-NE populations, we performed a drug screen and demonstrated that MEK inhibitors are selectively efficacious against non-NE populations. We further evaluated the MEK inhibitor combination therapies with agents targeting NE populations (cisplatin, ABT-263 and JQ1), which effectively eliminated both NE and non-NE components in vitro. Our further study demonstrated that ABT-263 in combination with MEK inhibitors presented a synergistic effect, which could be a promising therapeutic combination for tSCLC patients. Conclusion: We demonstrate that the cancer cell lines established from tSCLC patients consist of heterogeneous population of cells with NE and non-NE/mesenchymal characteristics. The crosstalk between these two cell populations is observed and our findings underscore the importance of targeting tumor heterogeneity as a promising treatment strategy for patients with tSCLC. Citation Format: Atsuko Ogino, Xinmeng Jasmine Mu, Mika Lin, Antonio Calles, Stephen Wang, Man Xu, Lynette M. Scholl, Geoffrey R. Oxnard, Paul Kirschmeier, Pasi A. Jänne. Effective MEK inhibitor combinations to target tumor heterogeneity in EGFR mutant transformed SCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3783." @default.
• W4250069596 created "2022-05-12" @default.
• W4250069596 creator A5001798787 @default.
• W4250069596 creator A5022816998 @default.
• W4250069596 creator A5027888245 @default.
• W4250069596 creator A5034758372 @default.
• W4250069596 creator A5037098485 @default.
• W4250069596 creator A5037451699 @default.
• W4250069596 creator A5045665778 @default.
• W4250069596 creator A5048675362 @default.
• W4250069596 creator A5051597781 @default.
• W4250069596 creator A5090452503 @default.
• W4250069596 date "2019-07-01" @default.
• W4250069596 modified "2023-10-17" @default.
• W4250069596 title "Abstract 3783: Effective MEK inhibitor combinations to target tumor heterogeneity in <i>EGFR</i> mutant transformed SCLC" @default.
• W4250069596 doi "https://doi.org/10.1158/1538-7445.am2019-3783" @default.
• W4250069596 hasPublicationYear "2019" @default.
• W4250069596 type Work @default.
• W4250069596 citedByCount "0" @default.
• W4250069596 crossrefType "journal-article" @default.
• W4250069596 hasAuthorship W4250069596A5001798787 @default.
• W4250069596 hasAuthorship W4250069596A5022816998 @default.
• W4250069596 hasAuthorship W4250069596A5027888245 @default.
• W4250069596 hasAuthorship W4250069596A5034758372 @default.
• W4250069596 hasAuthorship W4250069596A5037098485 @default.
• W4250069596 hasAuthorship W4250069596A5037451699 @default.
• W4250069596 hasAuthorship W4250069596A5045665778 @default.
• W4250069596 hasAuthorship W4250069596A5048675362 @default.
• W4250069596 hasAuthorship W4250069596A5051597781 @default.
• W4250069596 hasAuthorship W4250069596A5090452503 @default.
• W4250069596 hasBestOaLocation W42500695961 @default.
• W4250069596 hasConcept C121608353 @default.
• W4250069596 hasConcept C126322002 @default.
• W4250069596 hasConcept C142724271 @default.
• W4250069596 hasConcept C1491633281 @default.
• W4250069596 hasConcept C2776232967 @default.
• W4250069596 hasConcept C2776256026 @default.
• W4250069596 hasConcept C2777506169 @default.
• W4250069596 hasConcept C2779438470 @default.
• W4250069596 hasConcept C2908647359 @default.
• W4250069596 hasConcept C502942594 @default.
• W4250069596 hasConcept C54355233 @default.
• W4250069596 hasConcept C71924100 @default.
• W4250069596 hasConcept C81885089 @default.
• W4250069596 hasConcept C86803240 @default.
• W4250069596 hasConcept C99454951 @default.
• W4250069596 hasConceptScore W4250069596C121608353 @default.
• W4250069596 hasConceptScore W4250069596C126322002 @default.
• W4250069596 hasConceptScore W4250069596C142724271 @default.
• W4250069596 hasConceptScore W4250069596C1491633281 @default.
• W4250069596 hasConceptScore W4250069596C2776232967 @default.
• W4250069596 hasConceptScore W4250069596C2776256026 @default.
• W4250069596 hasConceptScore W4250069596C2777506169 @default.
• W4250069596 hasConceptScore W4250069596C2779438470 @default.
• W4250069596 hasConceptScore W4250069596C2908647359 @default.
• W4250069596 hasConceptScore W4250069596C502942594 @default.
• W4250069596 hasConceptScore W4250069596C54355233 @default.
• W4250069596 hasConceptScore W4250069596C71924100 @default.
• W4250069596 hasConceptScore W4250069596C81885089 @default.
• W4250069596 hasConceptScore W4250069596C86803240 @default.
• W4250069596 hasConceptScore W4250069596C99454951 @default.
• W4250069596 hasIssue "13_Supplement" @default.
• W4250069596 hasLocation W42500695961 @default.
• W4250069596 hasOpenAccess W4250069596 @default.
• W4250069596 hasPrimaryLocation W42500695961 @default.
• W4250069596 hasRelatedWork W2007766970 @default.
• W4250069596 hasRelatedWork W2107312379 @default.
• W4250069596 hasRelatedWork W2165426291 @default.
• W4250069596 hasRelatedWork W2769380588 @default.
• W4250069596 hasRelatedWork W2981451520 @default.
• W4250069596 hasRelatedWork W3042289395 @default.
• W4250069596 hasRelatedWork W3044237032 @default.
• W4250069596 hasRelatedWork W3200680356 @default.
• W4250069596 hasRelatedWork W4281683971 @default.
• W4250069596 hasRelatedWork W4323293855 @default.
• W4250069596 hasVolume "79" @default.
• W4250069596 isParatext "false" @default.
• W4250069596 isRetracted "false" @default.
• W4250069596 workType "article" @default.